Bansisons Tea Industries Ltd (NOVYRA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Bansisons Tea Industries Ltd on NSE and BSE, with an AI summary of each filing.
Unaudited Financial Results for the quarter ended September 30, 2026
Financial Result · 02 Nov 2026, 11:21 pm
Novyra Pharmachem Reports Q2 Results with Widening Net Loss Despite Revenue Surge Novyra Pharmachem reported total revenue of ₹426.78 lakh for the quarter ended 30th Sep'26, jumping sharply from ₹3.31 lakh YoY and ₹172.61 lakh QoQ, driven primarily by ₹423.08 lakh from its Pharma segment. Despite top-line expansion, total expenses rose to ₹430.10 lakh due to ₹414.02 lakh in stock purchases, leading to a net loss of ₹3.32 lakh compared to a profit of ₹0.10 lakh YoY and a loss of ₹1.99 lakh QoQ. Diluted EPS stood at ₹(0.05).
Unaudited financial results for the quarter ended September 30, 2026
Outcome · 02 Nov 2026, 11:13 pm
Bansisons Tea Industries Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs) ■ Revenue: 423 (+145.1% QoQ) ■ EBITDA: -6.7 (-171.0% YoY | -297.6% QoQ) ■ EBITDA Margin (%): -1.6 (-61 bps QoQ) ■ PAT: -3.3 (Profit to Loss YoY | -67.3% QoQ) ■ EPS (INR): -0.05 (-66.7% QoQ) Bansisons Tea Industries Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs) Segmental Performance Pharma ■ Revenue: 423 (+145.1% QoQ) ■ EBIT: 3.2 (+148.1% QoQ) ■ EBIT Margin (%): 0.8 (+1 bps QoQ) Real Estate ■ Revenue: 3.7 ■ EBIT: 0.0 ■ EBIT Margin (%): 0.0 Tea Estate ■ Revenue: 0.0 ■ EBIT: 0.0 ■ EBIT Margin (%): 0.0 Unallocable ■ Revenue: 0.0 (-100.0% YoY) ■ EBIT: -6.5 (Profit to Loss YoY | -98.8% QoQ) ■ EBIT Margin (%): 0.0 (-302 bps YoY)
Novyra Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Un-Audited Financial Results ....
Intimation · 02 Nov 2026, 5:30 am
Novyra Pharmachem Schedules Board Meeting for Q2 FY27 Financial Results Novyra Pharmachem Limited has informed BSE that its Board of Directors is scheduled to meet on 2nd Nov'26. The board will inter alia consider and approve the company's unaudited financial results for the second quarter ended 30th Sep'26, along with the Auditor's Limited Review Report.
Intimation under Reg 30
Others (Uncategorized) · 24 Sept 2026, 7:35 pm
Novyra Pharmachem Updates Official Corporate Email Address Novyra Pharmachem Limited (formerly Bansisons Tea Industries Ltd) informed BSE under Regulation 30 of SEBI LODR Regulations, 2015, regarding the immediate change of its official email ID on 24th Sep'26. The company’s official communication and investor grievance email has been updated from bansisonstea@gmail.com to novyrapharmachemlimited@gmail.com for all future corporate correspondences.
Reg 30
Others (Uncategorized) · 22 Aug 2026, 7:33 pm
Bansisons Tea Industries Renamed Novyra Pharmachem to Reflect Pharma Focus Bansisons Tea Industries Limited (BSE: 519353) has been renamed Novyra Pharmachem Limited, effective from 19th Jan'26. This change reflects its strategic expansion into the pharmaceutical and life sciences sectors. The company will now focus on manufacturing and trading APIs, bulk drugs, and specialty chemicals, alongside offering contract research (CRO) and development manufacturing (CDMO) services. This move signals a significant pivot from its previous business into higher-growth pharma-related activities. The company will update its name with exchanges and depositories.
Quarterly Results June 30, 2026
Financial Result · 14 Aug 2026, 11:43 pm
Novyra Pharmachem Reports Q1FY27 Loss on Strong Pharma Segment Revenue Growth Novyra Pharmachem reported a net loss of ₹1.99 Lakhs for Q1FY27, a slight improvement from a ₹533.83 Lakh loss in Q4FY26 but worse than the ₹0.77 Lakh loss in Q1FY26. Revenue from operations surged to ₹172.61 Lakhs, up significantly from ₹3.00 Lakhs YoY and ₹10.44 Lakhs QoQ. The growth was driven by the Pharma segment, which generated ₹172.61 Lakhs in revenue and a profit of ₹1.29 Lakhs. The overall loss was due to large losses in the now-discontinued Tea Estate segment in previous periods.
Quarterly Results June 30, 2026
Outcome · 14 Aug 2026, 11:37 pm
Bansisons Tea Industries Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 173 (+1553.4% QoQ) ■ EBITDA: -1.7 (+44.6% YoY | +99.7% QoQ) ■ EBITDA Margin (%): -1.0 (+510534 bps QoQ) ■ PAT: -2.0 (-158.4% YoY | +99.6% QoQ) ■ EPS (INR): -0.03 (-200.0% YoY | +99.6% QoQ) Bansisons Tea Industries Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) Segmental Performance Pharma ■ Revenue: 173 (+17161.0% QoQ) ■ EBIT: 1.3 (+29.0% QoQ) ■ EBIT Margin (%): 0.7 (-9925 bps QoQ) Real Estate ■ Revenue: 0.0 (-100.0% QoQ) ■ EBIT: 0.0 (-100.0% QoQ) ■ EBIT Margin (%): 0.0 (-10000 bps QoQ) Tea Estate ■ Revenue: 0.0 (-100.0% QoQ) ■ EBIT: 0.0 (Loss to Profit QoQ) ■ EBIT Margin (%): 0.0 (Loss to Profit QoQ)
Bansisons Tea Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Quarterly Results June 30, 2026
Intimation · 14 Aug 2026, 5:30 am
Novyra Pharmachem Board Meeting Set for Q1 Results Novyra Pharmachem Limited (BSE: 519353) has scheduled a Board of Directors meeting on 14th Aug'26. The primary agenda is to consider and approve the unaudited financial results for the first quarter ending 30th Jun'26. The results will be accompanied by the Auditor's Limited Review Report. The company was formerly known as Bansisons Tea Industries Ltd.
Change of Website
Others (Uncategorized) · 04 Aug 2026, 11:16 pm
Novyra Pharmachem Announces Official Website Address Change Novyra Pharmachem Limited (formerly Bansisons Tea Industries Ltd) has officially changed its website address. Effective 4th Aug'26, the company's new website is www.novyrapharmachemltd.com, replacing the old address, www.bansisonstea.com. This update aligns with the company's rebranding and ensures all regulatory disclosures required under SEBI regulations are now available on the new site. The company has notified the BSE (Scrip Code: 519353) to update its records.
Voting Results AGM
Annual General Meeting · 26 Jun 2026, 10:10 pm
Proceedings of 39th AGM
Annual General Meeting · 25 Jun 2026, 5:58 pm
Annual Report 2025-2026
Others (Uncategorized) · 05 Jun 2026, 11:17 pm
Novyra Pharmachem Seeks Approval for Major Capital Reduction to Offset Losses Novyra Pharmachem Ltd. has released its FY26 annual report, proposing a significant capital reduction to write off accumulated losses. The company reported a net loss of Rs. 537.38 lakhs for FY26, widening from a loss of Rs. 6.36 lakhs in FY25. Revenue was Rs. 16.75 lakhs. The Board seeks shareholder approval via special resolution to reduce paid-up equity capital from Rs. 6.33 crore to Rs. 90.43 lakhs, cancelling 85.71% of shares to offset Rs. 5.43 crore in losses. The 39th AGM is scheduled for 25th Jun'26.
Annual Report 2025-2026
Annual Report · 02 Jun 2026, 1:37 am
AGM Notice
Annual General Meeting · 02 Jun 2026, 1:35 am
Novyra Pharmachem Proposes 85.7% Capital Reduction to Write Off Accumulated Losses Novyra Pharmachem will seek shareholder approval at its AGM on 25 Jun'26 for a Scheme of Capital Reduction. The proposal involves reducing paid-up equity share capital by 85.71% from Rs. 6.33 crore to Rs. 90.42 lakh. This will be achieved by cancelling 54.25 million shares of Rs. 10 each. The reduction aims to write off Rs. 5.42 crore of accumulated losses against the share capital, strengthening the balance sheet. Post-reduction, retained losses will be Rs. 28.22 lakh. Shareholding percentages will remain unchanged.
Reg 32
Others (Uncategorized) · 30 May 2026, 6:07 pm
Novyra Pharmachem Confirms Capital Base Increase and No Fund Diversion Novyra Pharmachem confirms no deviation in the utilization of proceeds from its preferential issue. On 28th Mar'25 and 9th Jun'25, the board converted 1,76,600 partly paid-up shares into fully paid-up shares. This action increased the total paid-up share capital to ₹6.33 crore, comprising 63,30,000 equity shares of ₹10 each. The funds raised were for working capital requirements. The disclosure, reviewed by the Audit Committee, is for the quarter and year ended 31st Mar'26. There were no comments from auditors.
As per attached pdf
Annual General Meeting · 27 May 2026, 12:43 am
Novyra Pharmachem Revises Key Dates for its 39th Annual General Meeting Novyra Pharmachem Limited has issued a revised notice for its 39th Annual General Meeting (AGM), correcting a previous submission. The AGM is now scheduled for Thu, 25th Jun'26, at 11:30 A.M. via VC/OAVM. The company updated key dates, setting the e-voting cut-off for Thu, 18th Jun'26, the remote e-voting period from Mon, 22nd Jun'26 to Wed, 24th Jun'26, and the book closure period from 19th Jun'26 to 25th Jun'26. Other details from the original notice remain unchanged.
As per attached pdf
Others (Uncategorized) · 27 May 2026, 12:32 am
Novyra Pharmachem Revises Key Dates for 39th AGM Novyra Pharmachem Limited announced revised dates for its 39th Annual General Meeting, which will be held via VC/OAVM on 25th Jun'26. The new cut-off date for e-voting eligibility is 18th Jun'26. The remote e-voting period is now scheduled from 22nd Jun'26 to 24th Jun'26. Correspondingly, the book closure dates have been revised to run from 19th Jun'26 to 25th Jun'26. The revisions were approved by the board on 26th May'26 to correct inadvertent errors in a prior submission.
Reduction of Capital and AGM
Outcome · 16 May 2026, 11:47 pm
Novyra Pharmachem Approves Capital Reduction Proposal and AGM Schedule Novyra Pharmachem's Board approved a proposal for capital reduction on 16th May'26, subject to regulatory and shareholder approvals. The Board also approved the Director's and Secretarial Audit Reports for the year ended 31st Mar'26. The 39th Annual General Meeting (AGM) is scheduled for 19th Jun'26 via video conference. The register of members and share transfer books will be closed from 13th Jun'26 to 19th Jun'26 for the purpose of the AGM. Mrs. Rupal Patel was appointed as Scrutinizer.
Bansisons Tea Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2026 ,inter alia, to consider and approve Reduction in Capital
Intimation · 04 May 2026, 11:28 pm
Novyra Pharmachem to Consider Capital Reduction on May 16 Novyra Pharmachem Limited (Scrip Code: 519353) has scheduled a Board of Directors meeting for Saturday, 16 May'26. The primary agenda item is to consider and approve a proposal for Capital Reduction under Section 66 of the Companies Act, 2013. The Board will also fix the date for the upcoming Annual General Meeting (AGM), decide on book closure dates, and approve the Director's and Secretarial Audit Reports for the year ended 31 Mar'26.
Audited Financial Results for the Quarter and Year ended on 31st March 2026 along with Auditors Report
Financial Result · 02 May 2026, 10:49 pm
NOVYRA PHARMACHEM LIMITED - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 10.4 ■ EBITDA: -533 (-8126.9% YoY | -24580.6% QoQ) ■ EBITDA Margin (%): -5106 ■ PAT: -534 (-10534.1% YoY | -18435.8% QoQ) ■ EPS (INR): -8.43 (-10437.5% YoY | -16760.0% QoQ) NOVYRA PHARMACHEM LIMITED - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) Segmental Performance Pharma ■ Revenue: 1.0 ■ EBIT: 1.0 ■ EBIT Margin (%): 100 Real Estate ■ Revenue: 0.5 ■ EBIT: 0.5 ■ EBIT Margin (%): 100 Tea Estate ■ Revenue: 8.9 ■ EBIT: -449 ■ EBIT Margin (%): -5027
Audited Financial Results of the Company for the quarter and year ended March 31, 2026 along with Auditors Report
Outcome · 02 May 2026, 10:41 pm
Novyra Pharmachem Reports FY26 Results with Significant Net Loss and Revenue Growth Novyra Pharmachem reported FY26 results with a net loss widening to ₹537.38 lakh from ₹6.36 lakh YoY. Total revenue increased significantly to ₹16.75 lakh from ₹4.80 lakh YoY. For Q4 FY26, the company posted a net loss of ₹533.83 lakh on revenue of ₹10.44 lakh. On an annual basis, the Tea Estate segment was the largest revenue contributor at ₹12.25 lakh but also recorded the highest segment loss of ₹446.64 lakh. Total assets decreased to ₹145.88 lakh from ₹614.42 lakh YoY as of 31 Mar'26.
Bansisons Tea Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2026 ,inter alia, to consider and approve Audited Financial ....
Intimation · 02 May 2026, 5:30 am
Novyra Pharmachem Reschedules Board Meeting for Q4 and FY26 Results Novyra Pharmachem Limited (BSE: 519353) has postponed its Board of Directors meeting, originally scheduled for 29th Apr'26. The meeting has been rescheduled to 02nd May'26. The agenda remains to consider and approve the Audited Financial Results for the quarter and year ended 31st Mar'26, along with the Auditor's Report.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 30 Apr 2026, 12:51 am
Novyra Pharmachem Confirms It Is Not a 'Large Corporate' Novyra Pharmachem Limited (BSE: 519353), formerly Bansisons Tea Industries Ltd, has confirmed to the exchange on 29th Apr'26 that it does not meet the criteria to be classified as a 'Large Corporate'. This is based on the SEBI circular dated 19th Oct'23 concerning fund-raising by large entities via debt securities. The company reported outstanding borrowings of ₹0.82 cr and does not have a credit rating. Consequently, the mandatory borrowing framework for Large Corporates is not applicable to Novyra Pharmachem.
Bansisons Tea Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2026 ,inter alia, to consider and approve Audited Financial ....
Rescheduled / Cancelled · 29 Apr 2026, 5:30 am
Novyra Pharmachem Reschedules Board Meeting for Financial Results Novyra Pharmachem Ltd (BSE: 519353) has postponed and rescheduled its Board of Directors meeting. The meeting, originally set for 25th Apr'26, will now be held on Wednesday, 29th Apr'26. The agenda remains to consider and approve the audited financial results for the quarter and year ended 31st Mar'26, along with the auditor's report. This revision follows an earlier intimation made on 18th Apr'26.
Bansisons Tea Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/04/2026 ,inter alia, to consider and approve Audited financial ....
Intimation · 18 Apr 2026, 5:30 am
Novyra Pharmachem to Announce Q4 and FY26 Results on Apr 18, 2026 Novyra Pharmachem Limited's Board of Directors will meet on 18th Apr'26 to consider and approve the audited financial results for the quarter and financial year ended 31st Mar'26. The company also confirmed its trading window for designated persons has been closed from 01st Apr'26 and will reopen 48 hours after the results are declared. This is pursuant to SEBI's insider trading regulations.